ArticleOxidative medicine and cellular longevity2022
Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory
Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Variant Angina is Associated with Myocarditis.Journal of inflammation research · 2022Trial
- Prognostic significance of high Lipoprotein(a) levels in patients with coronary artery spasm.Heart and vessels · 2026Article
- Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis.Frontiers in immunology · 2026Article
- The biology of lipoprotein(a): From genetics to molecular mechanisms.European journal of clinical investigation · 2026Review
- Lipoprotein(a) and Cardiovascular Risk: Emerging Therapeutic Perspectives with Implications for Chronic Kidney Disease.Cardiorenal medicine · 2026Review
- Lipoprotein(a)/CD36 Interaction Drives IL-6/RhoA-GTP Signaling and miRNA Epigenetic Regulation in Coronary Artery Spasm.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Lipoprotein (a): Underrecognized Risk with a Promising Future.Reviews in cardiovascular medicine · 2024Review
- MINOCA: A Pathophysiological Approach of Diagnosis and Treatment-A Narrative Review.Biomedicines · 2024Review
- Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis.Current atherosclerosis reports · 2024Review
- An integral perspective of canonical cigarette and e-cigarette-related cardiovascular toxicity based on the adverse outcome pathway framework.Journal of advanced research · 2023Review
- Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review.International journal of molecular sciences · 2023Review
- Article
- Luteolin suppresses the growth of colon cancer cells by inhibiting the IL-6/STAT3 signaling pathway.Journal of gastrointestinal oncology · 2022Article
- Non-linear Associations Between Visceral Adiposity Index and Cardiovascular and Cerebrovascular Diseases: Results From the NHANES (1999-2018).Frontiers in cardiovascular medicine · 2022Article
- Lipoprotein (a) in the context of atherosclerosis: pathological implications and therapeutic perspectives in myocardial infarction. A narrative review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveApolipoprotein (a)/lipoprotein(a) (Lp(a)), a major carrier of oxidized phospholipids, and
methodsWe investigated the relevance of Lp(a)/
resultsThere are increased serum Lp(a) levels (3.98-fold,
conclusionsElevated Lp(a) levels upregulate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.